Zenas BioPharma, Inc./$ZBIO
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Zenas BioPharma, Inc.
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Ticker
$ZBIO
Sector
Primary listing
Employees
167
Headquarters
Website
ZBIO Metrics
BasicAdvanced
$1bn
-
-$8.44
-
-
Price and volume
Market cap
$1bn
52-week high
$44.60
52-week low
$8.51
Average daily volume
865k
Financial strength
Current ratio
5.605
Quick ratio
5.497
Long term debt to equity
0.087
Total debt to equity
0.548
Interest coverage (TTM)
-28.85%
Profitability
EBITDA (TTM)
-211.329
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-3,777.37%
Operating margin (TTM)
-2,113.85%
Effective tax rate (TTM)
0.02%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-35.06%
Return on equity (TTM)
-136.22%
Valuation
Price to revenue (TTM)
78.501
Price to book
3.95
Price to tangible book (TTM)
3.95
Price to free cash flow (TTM)
-3.786
Free cash flow yield (TTM)
-26.41%
Free cash flow per share (TTM)
-4.636
Growth
Revenue change (TTM)
100.00%
Earnings per share change (TTM)
-29.00%
3-year earnings per share growth (CAGR)
-52.73%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zenas BioPharma, Inc. stock?
Zenas BioPharma, Inc. (ZBIO) has a market cap of $1B as of April 30, 2026.
What is the P/E ratio for Zenas BioPharma, Inc. stock?
The price to earnings (P/E) ratio for Zenas BioPharma, Inc. (ZBIO) stock is 0 as of April 30, 2026.
Does Zenas BioPharma, Inc. stock pay dividends?
No, Zenas BioPharma, Inc. (ZBIO) stock does not pay dividends to its shareholders as of April 30, 2026.
When is the next Zenas BioPharma, Inc. dividend payment date?
Zenas BioPharma, Inc. (ZBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Zenas BioPharma, Inc.?
Zenas BioPharma, Inc. (ZBIO) does not currently have a Beta indicator.